Abstract
Many potential HIV vaccine strategies are being explored in both animal model and human settings. The success of any vaccine relies on relevant antigenic determinants being presented to the immune system for the activation of broad and long-lasting immunity. Effective immunity against HIV infection will likely require both the cellular and humoral arms of the immune system, where HIVspecific killer cells eradicate infected targets and neutralizing antibody responses contribute by preventing the initial infection of host cells. As the most potent antigen presenting cell of the immune system, the dendritic cell (DC) orchestrates the activation of adaptive immune responses as well as contributing to the early innate responses to a pathogen, which may also aid in the initial control of infection. It follows therefore, that the efficiency of a vaccine antigen would be greatly enhanced if targeted to the appropriate DCs to ensure optimal presentation to and subsequently activation of the immune system. This review will discuss (i) the current status of DC biology, covering distinct DC subsets and stages of activation and how these influence the types of immune responses that are induced, (ii) how DCs can be exploited to improve the efficacy of HIV vaccine strategies currently under investigation, (iii) what has been learned from in vivo model systems using DCs, and (iv) future considerations to advance HIV vaccinology.
Keywords: dendritic cells, hiv vaccines, humoral arms, dc, orchestrates, adaptive immune responses, dc biology, hiv vaccinology
Current Molecular Medicine
Title: Dendritic Cells as A Conduit to Improve HIV Vaccines
Volume: 3 Issue: 3
Author(s): Melissa Pope
Affiliation:
Keywords: dendritic cells, hiv vaccines, humoral arms, dc, orchestrates, adaptive immune responses, dc biology, hiv vaccinology
Abstract: Many potential HIV vaccine strategies are being explored in both animal model and human settings. The success of any vaccine relies on relevant antigenic determinants being presented to the immune system for the activation of broad and long-lasting immunity. Effective immunity against HIV infection will likely require both the cellular and humoral arms of the immune system, where HIVspecific killer cells eradicate infected targets and neutralizing antibody responses contribute by preventing the initial infection of host cells. As the most potent antigen presenting cell of the immune system, the dendritic cell (DC) orchestrates the activation of adaptive immune responses as well as contributing to the early innate responses to a pathogen, which may also aid in the initial control of infection. It follows therefore, that the efficiency of a vaccine antigen would be greatly enhanced if targeted to the appropriate DCs to ensure optimal presentation to and subsequently activation of the immune system. This review will discuss (i) the current status of DC biology, covering distinct DC subsets and stages of activation and how these influence the types of immune responses that are induced, (ii) how DCs can be exploited to improve the efficacy of HIV vaccine strategies currently under investigation, (iii) what has been learned from in vivo model systems using DCs, and (iv) future considerations to advance HIV vaccinology.
Export Options
About this article
Cite this article as:
Pope Melissa, Dendritic Cells as A Conduit to Improve HIV Vaccines, Current Molecular Medicine 2003; 3 (3) . https://dx.doi.org/10.2174/1566524033479870
DOI https://dx.doi.org/10.2174/1566524033479870 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Efficacy of TNF Antagonists Beyond One Year in Adult and Pediatric Inflammatory Bowel Diseases: A Systematic Review
Current Drug Targets NOX3-Targeted Therapies for Inner Ear Pathologies
Current Pharmaceutical Design Mechanisms Involved in the Protective Effects of Metformin Against Nonalcoholic Fatty Liver Disease
Current Medicinal Chemistry Advances in Sickle Cell Disease Treatment: from Drug Discovery Until the Patient Monitoring
Cardiovascular & Hematological Agents in Medicinal Chemistry MicroRNA Involvement in the Pathogenesis of Neuroblastoma: Potential for MicroRNA Mediated Therapeutics
Current Pharmaceutical Design Before and After Preeclampsia: What Biomarkers are there?
Current Women`s Health Reviews Plant-Derived Bioactive Compounds Produced by Endophytic Fungi
Mini-Reviews in Medicinal Chemistry Stem Cell-Like Brain Cancer Cells
Current Cancer Therapy Reviews Clinical Aspects of Melatonin in the Acute Coronary Syndrome
Current Vascular Pharmacology Hereditary Rickets. How Genetic Alterations Explain the Biochemical and Clinical Phenotypes
Endocrine, Metabolic & Immune Disorders - Drug Targets Inhibition of Angiogenesis as a Treatment Strategy for Neuroblastoma
Current Cancer Therapy Reviews PepT1, ASBT-Linked Prodrug Strategy to Improve Oral Bioavailability and Tissue Targeting Distribution
Current Drug Metabolism Smac-Derived Aza-Peptide As an Aminopeptidase-Resistant XIAP BIR3 Antagonist
Protein & Peptide Letters Heteroarylacetyl Chlorides and Mixed Anhydrides as Intermediates in the Synthesis of Heterocyclic Dronic Acids
Letters in Drug Design & Discovery Therapeutic Approaches to the Challenge of Neuronal Ceroid Lipofuscinoses
Current Pharmaceutical Biotechnology Follow the ATP: Tumor Energy Production: A Perspective
Anti-Cancer Agents in Medicinal Chemistry Pediatric Oral Lichen Planus: Review and Case Report
Current Pediatric Reviews Zoledronic Acid: Pleiotropic Anti-Tumor Mechanism and Therapeutic Outlook for Osteosarcoma
Current Drug Targets Editorial [Hot Topic: Current Drug Targets in Childhood Acute Leukemia (Guest Editor: R.B. Lock)]
Current Drug Targets Patent Selections:
Recent Patents and Topics on Imaging (Discontinued)